Evidence map›Paper›PMID 42517238›Full record

ArticleAnnals of clinical and translational neurology2026

Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder.

Felix Wohlrab, Evelyn Alvarez, Roua Hamdi, Bingqing Zhang, Hayeun Ji, Niyati Jhaveri, Patrick Schindler, Pedro Sanchez, Pia S Sperber, Tanja Schmitz-Hübsch and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Felix WohlrabExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-1396-4138
Evelyn AlvarezAlamar Biosciences, Fremont, California, USA.
Roua HamdiExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Bingqing ZhangAlamar Biosciences, Fremont, California, USA.
Hayeun JiAlamar Biosciences, Fremont, California, USA.
Niyati JhaveriAlamar Biosciences, Fremont, California, USA.
Patrick SchindlerNeuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-8846-121X
Pedro SanchezNeuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Pia S SperberNeuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Tanja Schmitz-HübschNeuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-4833-5937
Frederike C OertelExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-4906-5983
Nisa VorasootDivision of Neurology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Najib KissaniLaboratory of Clinical and Experimental Neuroscience, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco.
Falko BöhringerLabor Berlin - Charité Vivantes Services GmbH, Berlin, Germany.
Jens KuhleMultiple Sclerosis Center and Research Centers for Clinical Neuroimmunology and Neuroscience (RC2NB) Neurology, University and University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-6963-8892
Anne-Katrin PröbstelMultiple Sclerosis Center and Research Centers for Clinical Neuroimmunology and Neuroscience (RC2NB) Neurology, University and University Hospital Basel, Basel, Switzerland.
Xiao-Jun MaAlamar Biosciences, Fremont, California, USA.
Péter KörtvelyessyDepartment of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Patrick WatersOxford Autoimmune Neurology Diagnostic Laboratory, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Friedemann PaulExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-6378-0070

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma- and serum-GFAP testing for assessment of disease severity in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG

methodsA neuroimmunological prospective cohort of remission samples from 70 participants with the diagnoses AQP4-IgG

resultsGFAP concentrations measured by NULISA correlated strongly between plasma and DPS samples across diagnostic groups and healthy controls. In NMOSD, plasma GFAP measured by NULISA showed strong concordance with serum GFAP quantified by Simoa. DPS-derived and plasma-derived GFAP demonstrated good diagnostic accuracy for AQP4-IgG

interpretationGFAP quantification using the NULISA platform is feasible in plasma and DPS samples and enables reliable biomarker assessment in a potentially remote-compatible setting. DPS-derived GFAP measurements retained meaningful information on disability in NMOSD and may provide an analytical framework for future studies evaluating minimally invasive capillary or self-sampling approaches.

Indexed as

clinical neuroimmunologydried blood spot samplingfluid biomarkersglial fibrillary acidic protein (GFAP)Neuromyelitis optica spectrum disorder (NMOSD)

Identifiers

PMID42517238
PMCPMC13409006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.